Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.

Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs

Abstract

INTRODUCTION: Currently available Alzheimer's disease (AD) therapeutics are only symptomatic, targeting cholinergic and glutamatergic neurotransmissions. Several putative disease-modifying drugs in late-stage clinical development target amyloid-β (Aβ) peptide and tau protein, the principal neurophatological hallmarks of the disease. AREAS COVERED: Phase III randomized clinical trials of anti-Aβ drugs for AD treatment were searched in US and EU clinical trial registries and principal biomedical databases until May 2020. EXPERT OPINION: At present, compounds in Phase III clinical development for AD include four anti-Ab monoclonal antibodies (solanezumab, gantenerumab, aducanumab, BAN2401), the combination of cromolyn sodium and ibuprofen (ALZT-OP1), and two small molecules (levetiracetam, GV-971). These drugs are mainly being tested in subjects during early AD phases or at preclinical stage of familial AD or even in asymptomatic subjects at high risk of developing AD. The actual results support the hypothesis that elevated Aβ represents an early stage in the AD continuum and demonstrate the feasibility of enrolling these high-risk participants in secondary prevention trials to slow cognitive decline during the AD preclinical stages. However, a series of clinical failures may question further development of Aβ-targeting drugs and the findings from current ongoing Phase III trials will hopefully give light to this critical issue.

Overview

Integrity signals

Registry

Crossref · 10.1080/14728214.2020.1808621

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 155 references

Research works printed but not linked: 10

  1. NICE, 2011, Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
  2. Panza F, 2019, Brain, 142, 2905
  3. Mandel RJ, 2010, Curr Opin Mol Ther, 12, 240
  4. Jaturapatporn D, 2012, Cochrane Database Syst Rev, CD006378
  5. Bussiere T, 2013, Neurodegener Dis, 11, 1
  6. Budd Haeberlein S, 2017, J Prev Alzheimers Dis, 4, 255
  7. Exposure, exposure, exposure? At CTAD, aducanumab scientists make a case 13 Dec 2019. [Last accessed 2020 Aug 5]. Available from: https://www.alzforum.org/news/conference-coverage/exposure-exposure-exposure-ctad-aducanumab-scientists-make-case
  8. Osswald G, BioArctic
  9. 7th Clinical Trials Conference on Alzheimer’s Disease (CTAD). Abstract OC3
  10. Fits and starts: trial results from the CTAD conference. [cited 2020 Aug 5]. Available from: https://www.alzforum.org/news/conference-coverage/fits-and-starts-trial-results-ctad-conference#Meiyu

Cited by

See all 87

Metadata

Authors
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., Bellomo, A., Seripa, D., & Panza, F.
Affiliations
  • University of Bari Aldo Moro (IT)
  • University of Foggia (IT)
  • Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
  • Gastroenterology Hospital "Saverio de Bellis" (IT)
  • Academic Center for Dentistry Amsterdam (NL)
  • Università Cattolica del Sacro Cuore (IT)
  • Casa Sollievo della Sofferenza (IT)
Corresponding author
  • Lozupone, Madia
  • Panza, Francesco
Venue
Expert Opinion on Emerging Drugs
Published
2020-07-02
Volume
25
Issue
3
Pages
319-335
ISSN
  • 1472-8214 (ISSN-L)
  • 1744-7623
OpenAlex
W3048331423
Cited by
77
References
155
Citations by year
2026: 5 · 2025: 5 · 2024: 9 · 2023: 14 · 2022: 24 · 2021: 15 · 2020: 5
FWCI
1.88
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Emerging Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
talian Ministry of Health with ‘Ricerca Corrente 2019’ Grant
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, amyloid-beta, disease-modifying therapy, monoclonal antibodies, solanezumab, gantenerumab, aducanumab, disodium cromoglycate, ibuprofen, levetiracetam, preclinical Alzheimer's disease, secondary prevention, cognitive decline, clinical trial results
MeSH terms
Drug Development, Alzheimer Disease, Animals, Antibodies, Monoclonal, Humans, Randomized Controlled Trials as Topic, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. https://app.cochat.ai/papers/10.1080/14728214.2020.1808621
The paper
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., Bellomo, A., Seripa, D., & Panza, F. (2020). Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opinion on Emerging Drugs. https://doi.org/10.1080/14728214.2020.1808621

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.